OverviewSuggest Edit

LYSOGENE is a company whose main activities include the basic research and clinical development of gene therapy for neurodegenerative disorders. The Company aims to radically improve the health of patients suffering from incurable life threatening conditions. LYSOGENE does this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

TypePublic
Founded2009
HQNeuilly-sur-Seine, FR
Websitelysogene.com

Latest Updates

Employees (est.) (Jul 2021)22
Share Price (Sept 2021)€2.5
Cybersecurity ratingAMore

Key People/Management at LYSOGENE

Ralph Laufer

Ralph Laufer

Chief Scientific Officer
Karen Pignet-Aiach

Karen Pignet-Aiach

Founder, Chair and CEO
Sophie Olivier

Sophie Olivier

Chief Medical Officer
Marie Deneux

Marie Deneux

Chief Regulatory Officer
Stéphane Durant des Aulnois

Stéphane Durant des Aulnois

Chief Financial Officer
Show more

LYSOGENE Office Locations

LYSOGENE has offices in Neuilly-sur-Seine and Cambridge
Neuilly-sur-Seine, FR (HQ)
18 Rue Jacques Dulud
Cambridge, MA, US
2 First St 18th floor
Show all (2)

LYSOGENE Financials and Metrics

LYSOGENE Revenue

Market capitalization (8-Sept-2021)

41.1m

Closing stock price (8-Sept-2021)

2.5
LYSOGENE's current market capitalization is €41.1 m.
Show all financial metrics

LYSOGENE Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

LYSOGENE Online and Social Media Presence

Embed Graph

LYSOGENE News and Updates

NOVASEP and LYSOGENE Announce Their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product

LYON, France and PARIS, May 26, 2020 /PRNewswire/ -- Novasep, a leading supplier of services and technologies for the life sciences industry, and Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the...

LYSOGENE Blogs

Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Second patient treated in the global adaptative-design clinical trial with LYS-GM101 Ongoing enrollment of a total of 16 patients in the UK, US and France Paris, France — 30 August […] The post Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy fo…

Lysogene Reports its Cash Position as of 30 June 2021

Cash and cash equivalents of €15.0 million1 as of 30 June 2021 Paris, France — 23 July 2021 at 08:00 am CET — Lysogene (FR0013233475 – LYS), a phase 3 […] The post Lysogene Reports its Cash Position as of 30 June 2021 appeared first on Lysogene.

Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis

Paris, France — 08 July 2021 at 06:00 pm CET — Lysogene (FR0013233475 – LYS), a gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that the […] The post Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangl…

Half-year liquidity contract statement for LYSOGENE

Paris, France — 05 July 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today presents […] The post Half-year liquidity contract statement for LYSOGENE appeared first on Lysogene.

LYSOGENE releases the results from June 25, 2021 ordinary annual and extraordinary general meeting

Shareholders approved all proposed resolutions Paris, France — 25 June 2021 at 06:00 pm CEST — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous […] The post LYSOGENE releases the results from June 25, 2021 ordinary annual and extraordinary general meet…

Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome

Strengthening of Lysogene’s pipeline with a new drug candidate for a pathology with high unmet medical need Lysogene will be responsible for development, manufacturing, regulatory activities and commercialization of the […] The post Lysogene Enters into an Exclusive Worldwide License Agreement with …
Show more

LYSOGENE Frequently Asked Questions

  • When was LYSOGENE founded?

    LYSOGENE was founded in 2009.

  • Who are LYSOGENE key executives?

    LYSOGENE's key executives are Ralph Laufer, Karen Pignet-Aiach and Sophie Olivier.

  • How many employees does LYSOGENE have?

    LYSOGENE has 22 employees.

  • Who are LYSOGENE competitors?

    Competitors of LYSOGENE include Teknova, Genematrix and OmniSeq.

  • Where is LYSOGENE headquarters?

    LYSOGENE headquarters is located at 18 Rue Jacques Dulud, Neuilly-sur-Seine.

  • Where are LYSOGENE offices?

    LYSOGENE has offices in Neuilly-sur-Seine and Cambridge.

  • How many offices does LYSOGENE have?

    LYSOGENE has 2 offices.